Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravaginal Artesunate for CIN2/3
NCT02354534Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2015
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of artesunate in cervical intraepithelial neoplasia (CIN) (4 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Number of Participants With Serious Adverse Events at 41 weeks. Started Feb 2015; status: completed.
02
Drugs
artesunate
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT02354534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02354534.